

IFN-α 1b Catalog # PVGS1090

## **Product Information**

Primary Accession Species	P01562 Human
Sequence	Cys24-Glu189 (Ala137Val), expressed with an N-terminal Met
Purity	> 96% as analyzed by SDS-PAGE > 96% as analyzed by HPLC
Endotoxin Level Biological Activity	Fully biologically active when compared to standard. The specific activity determined by an anti-viral assay is no less than 1.0 × 10 <sup>8</sup> IU/mg.
Expression System	E. coli
Theoretical Molecular Weight	19.5 kDa
Formulation	Lyophilized from a 0.2 Im filtered solution in PBS, pH 7.4, 4% mannitol, 1%
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles.

## **Additional Information**

Gene ID	3439;3447
Other Names	Interferon alpha-1/13, IFN-alpha-1/13, Interferon alpha-D, LeIF D, IFNA1
Target Background	At least 23 different variants of IFN-alpha are known. The individual proteins have molecular masses between 19-26 kDa and consist of proteins with lengths of 156-166 and 172 amino acids. All IFN-alpha subtypes possess a common conserved sequence region between amino acid positions 115-151 while the amino-terminal ends are variable. Many IFN-alpha subtypes differ in their sequences at only one or two positions. Naturally occurring variants also include proteins truncated by 10 amino acids at the carboxy-terminal end.

NameIFNA1FunctionProduced by macrophages, IFN-alpha have antiviral activities. Interferon<br/>stimulates the production of two enzymes: a protein kinase and an<br/>oligoadenylate synthetase.Cellular LocationSecreted.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.